Metraipolis › archive › dc_290baf9859ca

Benefit-risk evaluation of Fuzheng Yiliu Decoction combined with chemotherapy for treating non-small cell lung cancer using multicriteria decision analysis — Europe PMC PMID:41064094

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41064094
DOI
10.3389/fonc.2025.1627904
License (as archived)
solo-consultazione
Archived
2026-11-09T19:34:38.269Z
SHA-256 of the archived text
e7d2d94dbdfc1c8c2e2d81b75178091807b6bf08df4195be61873693bb106503
Stable URL of this page
https://metraipolis.com/documento/dc_290baf9859ca

How to cite

Benefit-risk evaluation of Fuzheng Yiliu Decoction combined with chemotherapy for treating non-small cell lung cancer using multicriteria decision analysis — Europe PMC PMID:41064094 — Europe PMC (en), https://europepmc.org/article/MED/41064094 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_290baf9859ca (Metraipolis archive dc_290baf9859ca, sha256 e7d2d94dbdfc1c8c2e2d81b75178091807b6bf08df4195be61873693bb106503)
BibTeX
@misc{dc290baf9859ca,
  title = {Benefit-risk evaluation of Fuzheng Yiliu Decoction combined with chemotherapy for treating non-small cell lung cancer using multicriteria decision analysis — Europe PMC PMID:41064094},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41064094},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_290baf9859ca; sha256 e7d2d94dbdfc1c8c2e2d81b75178091807b6bf08df4195be61873693bb106503},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41064094. Agents can read the archived copy with the MCP tool read_document.